Dr. Abud Bakri

Got it.

But we don't know.

We need to know the dynamics.

We don't know where it goes, how it goes.

In the phase one trial, it was just a safety.

There was no adverse effects.

In the phase two trial, it was very small, like 40 patients.

There was at least a positive signal on the ulcerative colitis.

And this was done in the United States or this was in Croatia?

pass muster for a phase one in the United States?

That's a good question.

The groups seem to be very robust and they do really good randomized control, double blind placebo control trials.

I think we're very United States centric.

We view ourselves as the premier science and we are the premier science.

So people kind of trust that more.

And there may be, you know, perverse incentives when it comes to different government bodies and like, you know, Soviet era research that might be, you know, pro fabrication when it comes to certain compounds that makes people hesitant.

Because there's a lot of like these Soviet era compounds that are not peptides or some of them are peptides that are fantastic.

They sound amazing.

But when they get tested, maybe they're not as potent as the Soviet data would suggest.

I always thought that the Russian stuff was like the really potent stuff that they didn't want anyone else to know about.